{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:01:38Z","timestamp":1787749298042,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study describes specific patterns of elevated inflammatory proteins in clinical subtypes of myasthenia gravis (MG) patients. MG is a chronic, autoimmune neuromuscular disease with antibodies most commonly targeting the acetylcholine receptors (AChRab), which causes fluctuating skeletal muscle fatigue. MG pathophysiology includes a strong component of inflammation, and a large proportion of patients with early onset MG additionally present thymus hyperplasia. Due to the fluctuating nature and heterogeneity of the disease, there is a great need for objective biomarkers as well as novel potential inflammatory targets. We examined the sera of 45 MG patients (40 AChRab seropositive and 5 AChRab seronegative), investigating 92 proteins associated with inflammation. Eleven of the analysed proteins were significantly elevated compared to healthy controls, out of which the three most significant were: matrix metalloproteinase 10 (MMP-10; p\u2009=\u20090.0004), transforming growth factor alpha (TGF-\u03b1; p\u2009=\u20090.0017) and extracellular newly identified receptor for advanced glycation end-products binding protein (EN-RAGE) (also known as protein S100-A12; p\u2009=\u20090.0054). Further, levels of MMP-10, C-X-C motif ligand 1 (CXCL1) and brain derived neurotrophic factor (BDNF) differed between early and late onset MG. These novel targets provide valuable additional insight into the systemic inflammatory response in MG.<\/jats:p>","DOI":"10.1038\/srep39716","type":"journal-article","created":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T10:13:28Z","timestamp":1483438408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients"],"prefix":"10.1038","volume":"7","author":[{"given":"Carl Johan","family":"Molin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Westerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rostedt","family":"Punga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,3]]},"reference":[{"key":"BFsrep39716_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1749-6632.2012.06791.x","volume":"1274","author":"A Gradolatto","year":"2012","unstructured":"Gradolatto, A. et al. Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17. Ann N Y Acad Sci 1274, 40\u20137 (2012).","journal-title":"Ann N Y Acad Sci"},{"key":"BFsrep39716_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli, M. N. & Sanders, D. B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8, 475\u201390 (2009).","journal-title":"Lancet Neurol"},{"key":"BFsrep39716_CR3","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","volume":"48","author":"A Vincent","year":"1985","unstructured":"Vincent, A. & Newsom-Davis, J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48, 1246\u201352 (1985).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFsrep39716_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch, W. et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7, 365\u20138 (2001).","journal-title":"Nat Med"},{"key":"BFsrep39716_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi, O., Hamuro, J., Motomura, M. & Yamanashi, Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69, 418\u201322 (2011).","journal-title":"Ann Neurol"},{"key":"BFsrep39716_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus, N. E. & Verschuuren, J. J. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14, 1023\u201336 (2015).","journal-title":"Lancet Neurol"},{"key":"BFsrep39716_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","volume":"263","author":"S Binks","year":"2016","unstructured":"Binks, S., Vincent, A. & Palace, J. Myasthenia gravis: a clinical-immunological update. J Neurol 263, 826\u201334 (2016).","journal-title":"J Neurol"},{"key":"BFsrep39716_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","volume":"12","author":"A Marx","year":"2013","unstructured":"Marx, A. et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimm Rev 12, 875\u201384 (2013).","journal-title":"Autoimm Rev"},{"key":"BFsrep39716_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2012.06780.x","volume":"1275","author":"M Benatar","year":"2012","unstructured":"Benatar, M., Sanders, D. B., Wolfe, G. I., McDermott, M. P. & Tawil, R. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci 1275, 17\u201322, (2012).","journal-title":"Ann N Y Acad Sci"},{"key":"BFsrep39716_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","volume":"356","author":"AR Punga","year":"2015","unstructured":"Punga, A. R., Andersson, M., Alimohammadi, M. & Punga, T. Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. J Neurol Sci 356, 90\u20136 (2015).","journal-title":"J Neurol Sci"},{"key":"BFsrep39716_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/acn3.24","volume":"1","author":"T Punga","year":"2014","unstructured":"Punga, T. et al. Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker. Ann Clin Transl Neurol 1, 49\u201358 (2014).","journal-title":"Ann Clin Transl Neurol"},{"key":"BFsrep39716_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jneuroim.2016.01.003","volume":"292","author":"T Punga","year":"2016","unstructured":"Punga, T. et al. Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. J Neuroimmunol 292, 21\u20136 (2016).","journal-title":"J Neuroimmunol"},{"key":"BFsrep39716_CR13","doi-asserted-by":"publisher","first-page":"25886","DOI":"10.1038\/srep25886","volume":"6","author":"A Uzawa","year":"2016","unstructured":"Uzawa, A. et al. Changes in inflammatory cytokine networks in myasthenia gravis. Sci Rep 6, 25886, doi: 10.1038\/srep25886 (2016).","journal-title":"Sci Rep"},{"key":"BFsrep39716_CR14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1136\/jnnp.2008.169367","volume":"81","author":"J Spillane","year":"2010","unstructured":"Spillane, J., Beeson, D. J. & Kullmann, D. M. Myasthenia and related disorders of the neuromuscular junction. J Neurol Neurosurg Psychiatry 81, 850\u20137 (2010).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFsrep39716_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki, A. 3rd et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55, 16\u201323 (2000).","journal-title":"Neurology"},{"key":"BFsrep39716_CR16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns, T. M., Conaway, M. & Sanders, D. B. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology 74, 1434\u201340 (2010).","journal-title":"Neurology"},{"key":"BFsrep39716_CR17","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PloS One 9, e95192, doi: 10.1371\/journal.pone.0095192 (2014).","journal-title":"PloS One"},{"key":"BFsrep39716_CR18","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1093\/nar\/gkr424","volume":"39","author":"M Lundberg","year":"2011","unstructured":"Lundberg, M., Eriksson, A., Tran, B., Assarsson, E. & Fredriksson, S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 39, e102, doi: 10.1093\/nar\/gkr424 (2011).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep39716_CR19","doi-asserted-by":"publisher","first-page":"R158","DOI":"10.1186\/cc8115","volume":"13","author":"L Lorente","year":"2009","unstructured":"Lorente, L. et al. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care 13, R158, doi: 10.1186\/cc8115 (2009).","journal-title":"Crit Care"},{"key":"BFsrep39716_CR20","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.4049\/jimmunol.173.8.5209","volume":"173","author":"H Toft-Hansen","year":"2004","unstructured":"Toft-Hansen, H., Nuttall, R. K., Edwards, D. R. & Owens, T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol 173, 5209\u201318 (2004).","journal-title":"J Immunol"},{"key":"BFsrep39716_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0165-5728(94)90009-4","volume":"55","author":"DM Karussis","year":"1994","unstructured":"Karussis, D. M. et al. Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol 55, 187\u201393 (1994).","journal-title":"J Neuroimmunol"},{"key":"BFsrep39716_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.neuroscience.2009.02.029","volume":"160","author":"M Guerra-Crespo","year":"2009","unstructured":"Guerra-Crespo, M. et al. Transforming growth factor-alpha induces neurogenesis and behavioral improvement in a chronic stroke model. Neuroscience 160, 470\u201383 (2009).","journal-title":"Neuroscience"},{"key":"BFsrep39716_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuroscience.2009.05.050","volume":"163","author":"RR Leker","year":"2009","unstructured":"Leker, R. R. et al. Transforming growth factor alpha induces angiogenesis and neurogenesis following stroke. Neuroscience 163, 233\u201343 (2009).","journal-title":"Neuroscience"},{"key":"BFsrep39716_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00726-010-0528-0","volume":"41","author":"J Goyette","year":"2011","unstructured":"Goyette, J. & Geczy, C. L. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids 41, 821\u201342 (2011).","journal-title":"Amino Acids"},{"key":"BFsrep39716_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1749-6632.1993.tb22873.x","volume":"681","author":"S Cohen-Kaminsky","year":"1993","unstructured":"Cohen-Kaminsky, S. et al. High IL-6 gene expression and production by cultured human thymic epithelial cells from patients with myasthenia gravis. Ann N Y Acad Sci 681, 97\u20139 (1993).","journal-title":"Ann N Y Acad Sci"},{"key":"BFsrep39716_CR26","doi-asserted-by":"publisher","first-page":"e0123546","DOI":"10.1371\/journal.pone.0123546","volume":"10","author":"V Yilmaz","year":"2015","unstructured":"Yilmaz, V. et al. Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK. PloS One 10, e0123546, doi: 10.1371\/journal.pone.0123546 (2015).","journal-title":"PloS One"},{"key":"BFsrep39716_CR27","doi-asserted-by":"publisher","first-page":"403460","DOI":"10.1155\/2013\/403460","volume":"2013","author":"YK Chuah","year":"2013","unstructured":"Chuah, Y. K., Basir, R., Talib, H., Tie, T. H. & Nordin, N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam 2013, 403460, doi: 10.1155\/2013\/403460 (2013).","journal-title":"Int J Inflam"},{"key":"BFsrep39716_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neubiorev.2015.12.006","volume":"62","author":"R Ray","year":"2016","unstructured":"Ray, R., Juranek, J. K. & Rai, V. RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. Neurosci Biobehav Rev 62, 48\u201355 (2016).","journal-title":"Neurosci Biobehav Rev"},{"key":"BFsrep39716_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00726-008-0097-7","volume":"36","author":"J Pietzsch","year":"2009","unstructured":"Pietzsch, J. & Hoppmann, S. Human S100A12: a novel key player in inflammation? Amino Acids 36, 381\u20139 (2009).","journal-title":"Amino Acids"},{"key":"BFsrep39716_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0079-6123(03)46021-4","volume":"146","author":"V Freund","year":"2004","unstructured":"Freund, V. & Frossard, N. Expression of nerve growth factor in the airways and its possible role in asthma. Prog Brain Res 146, 335\u201346 (2004).","journal-title":"Prog Brain Res"},{"key":"BFsrep39716_CR31","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","volume":"70","author":"MC Dalakas","year":"2008","unstructured":"Dalakas, M. C. Invited article: inhibition of B cell functions: implications for neurology. Neurology 70, 2252\u201360 (2008).","journal-title":"Neurology"},{"key":"BFsrep39716_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/1756285615605700","volume":"8","author":"MC Dalakas","year":"2015","unstructured":"Dalakas, M. C. Future perspectives in target-specific immunotherapies of myasthenia gravis. Ther Adv Neurol Disord 8, 316\u201327 (2015).","journal-title":"Ther Adv Neurol Disord"},{"key":"BFsrep39716_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","volume":"36","author":"R Aricha","year":"2011","unstructured":"Aricha, R., Mizrachi, K., Fuchs, S. & Souroujon, M. C. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 36, 135\u201341 (2011).","journal-title":"J Autoimmun"},{"key":"BFsrep39716_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","volume":"78","author":"Y Xie","year":"2016","unstructured":"Xie, Y. et al. Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients. Cytokine 78, 44\u20136 (2016).","journal-title":"Cytokine"},{"key":"BFsrep39716_CR35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mus.22070","volume":"44","author":"JC Roche","year":"2011","unstructured":"Roche, J. C. et al. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 44, 278\u201380,(2011).","journal-title":"Muscle Nerve"},{"key":"BFsrep39716_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2011.09.010","volume":"35","author":"SH Chang","year":"2011","unstructured":"Chang, S. H. et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35, 611\u201321 (2011).","journal-title":"Immunity"},{"key":"BFsrep39716_CR37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1684\/ecn.2015.0367","volume":"26","author":"N Chunjie","year":"2015","unstructured":"Chunjie, N., Huijuan, N., Zhao, Y., Jianzhao, W. & Xiaojian, Z. Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients. Eur Cytokine Netw 26, 61\u20136 (2015).","journal-title":"Eur Cytokine Netw"},{"key":"BFsrep39716_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/cei.12272","volume":"176","author":"A Uzawa","year":"2014","unstructured":"Uzawa, A., Kawaguchi, N., Himuro, K., Kanai, T. & Kuwabara, S. Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol 176, 232\u20137 (2014).","journal-title":"Clin Exp Immunol"},{"key":"BFsrep39716_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/ana.21628","volume":"66","author":"S Berrih-Aknin","year":"2009","unstructured":"Berrih-Aknin, S. et al. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol 66, 521\u201331 (2009).","journal-title":"Ann Neurol"},{"key":"BFsrep39716_CR40","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1084\/jem.171.5.1797","volume":"171","author":"B Moser","year":"1990","unstructured":"Moser, B., Clark-Lewis, I., Zwahlen, R. & Baggiolini, M. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J Exp Med 171, 1797\u20131802 (1990).","journal-title":"J Exp Med"},{"key":"BFsrep39716_CR41","doi-asserted-by":"publisher","first-page":"5596","DOI":"10.1128\/MCB.10.10.5596","volume":"10","author":"N Iida","year":"1990","unstructured":"Iida, N. & Grotendorst, G. R. Cloning and sequencing of a new gro transcript from activated human monocytes: expression in leukocytes and wound tissue. Mol Cell Biol 10, 5596\u20139 (1990).","journal-title":"Mol Cell Biol"},{"key":"BFsrep39716_CR42","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.161.5.2600","volume":"161","author":"U Lippert","year":"1998","unstructured":"Lippert, U. et al. Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol 161, 2600\u20138 (1998).","journal-title":"J Immunol"},{"key":"BFsrep39716_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1046\/j.1523-1747.2000.00034.x","volume":"115","author":"RM Devalaraja","year":"2000","unstructured":"Devalaraja, R. M. et al. Delayed wound healing in CXCR2 knockout mice. J Invest Dermatol 115, 234\u201344 (2000).","journal-title":"J Invest Dermatol"},{"key":"BFsrep39716_CR44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fncel.2014.00430","volume":"8","author":"F Calabrese","year":"2014","unstructured":"Calabrese, F. et al. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci 8, 430, doi: 10.3389\/fncel.2014.00430 (2014).","journal-title":"Front Cell Neurosci"},{"key":"BFsrep39716_CR45","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1084\/jem.189.5.865","volume":"189","author":"M Kerschensteiner","year":"1999","unstructured":"Kerschensteiner, M. et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189, 865\u201370 (1999).","journal-title":"J Exp Med"},{"key":"BFsrep39716_CR46","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.0711863105","volume":"105","author":"P Bekinschtein","year":"2008","unstructured":"Bekinschtein, P. et al. BDNF is essential to promote persistence of long-term memory storage. Proc Natl Acad Sci USA 105, 2711\u20136 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep39716_CR47","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.nlm.2007.08.018","volume":"89","author":"Y Lu","year":"2008","unstructured":"Lu, Y., Christian, K. & Lu, B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 89, 312\u201323 (2008).","journal-title":"Neurobiol Learn Mem"},{"key":"BFsrep39716_CR48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s004150050139","volume":"244","author":"VD Bohbot","year":"1997","unstructured":"Bohbot, V. D., Jech, R., Bures, J., Nadel, L. & Ruzicka, E. Spatial and nonspatial memory involvement in myasthenia gravis. J Neurol 244, 529\u201332 (1997).","journal-title":"J Neurol"},{"key":"BFsrep39716_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0022-510X(00)00367-1","volume":"179","author":"RH Paul","year":"2000","unstructured":"Paul, R. H., Cohen, R. A., Gilchrist, J. M., Aloia, M. S. & Goldstein, J. M. Cognitive dysfunction in individuals with myasthenia gravis. J Neurol Sci 179, 59\u201364 (2000).","journal-title":"J Neurol Sci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep39716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39716","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T14:35:38Z","timestamp":1692628538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep39716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,2]]}},"alternative-id":["BFsrep39716"],"URL":"https:\/\/doi.org\/10.1038\/srep39716","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,3]]},"assertion":[{"value":"21 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39716"}}